Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...

The ex-CytoDyn chief exec must also forfeit more than $4.4 million—approximately the amount he profited from the scheme—and ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

A federal grand jury in Rhode Island has charged two former top executives of Colorado-based medical device company Zynex Inc. | A federal grand jury in Rhode Island has charged two former top ...

Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Genomics and life sciences pioneer J. Craig Venter, Ph.D., is back with a new J. | Genomics and life sciences pioneer J.